First National Trust Co Has $7.41 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

First National Trust Co lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,965 shares of the medical research company’s stock after selling 1,168 shares during the period. First National Trust Co’s holdings in Thermo Fisher Scientific were worth $7,412,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Thermo Fisher Scientific by 1.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 82,690 shares of the medical research company’s stock worth $41,855,000 after acquiring an additional 997 shares during the period. Legacy Financial Group LLC bought a new stake in Thermo Fisher Scientific in the 3rd quarter valued at $104,000. Mn Services Vermogensbeheer B.V. increased its position in Thermo Fisher Scientific by 1.7% during the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 187,400 shares of the medical research company’s stock worth $94,856,000 after buying an additional 3,200 shares during the period. Guyasuta Investment Advisors Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.3% during the third quarter. Guyasuta Investment Advisors Inc. now owns 104,663 shares of the medical research company’s stock worth $52,977,000 after buying an additional 291 shares in the last quarter. Finally, Brown Advisory Inc. grew its stake in shares of Thermo Fisher Scientific by 0.6% in the third quarter. Brown Advisory Inc. now owns 2,066,694 shares of the medical research company’s stock valued at $1,046,098,000 after acquiring an additional 12,463 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders sold 62,277 shares of company stock worth $35,373,364 over the last three months. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent research reports. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Barclays boosted their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday, April 25th. Finally, Raymond James raised their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $607.35.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $1.13 during mid-day trading on Friday, hitting $572.38. 1,749,670 shares of the stock traded hands, compared to its average volume of 1,409,187. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The firm has a 50 day simple moving average of $575.39 and a two-hundred day simple moving average of $532.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The company has a market cap of $218.48 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.